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MitochondriaThehistidine triad (HIT) superfamily comprisesproteins that share thehistidine triadmotif,His-ϕ-His-ϕ-His-ϕ–ϕ,
whereϕ is a hydrophobic aminoacid.HITproteins areubiquitous inprokaryotesandeukaryotes.HITproteins bind
nucleotides and exert dinucleotidyl hydrolase, nucleotidylyl transferase or phosphoramidate hydrolase enzymatic
activity. In humans, 5 families of HIT proteins are recognized. The accumulated epidemiological and experimental
evidence indicates that two branches of the superfamily, the HINT (Histidine Triad Nucleotide Binding)members
and FHIT (Fragile Histidine Triad), have tumor suppressor properties but a conclusive physiological role can still
not be assigned to these proteins. Aprataxin forms another discrete branch of the HIT superfamily, is implicated in
DNArepairmechanisms andunlike theHINTand FHITmembers, a defectiveprotein canbeconclusively linked to a
disease, ataxia with oculomotor apraxia type 1. The scavenger mRNA decapping enzyme, DcpS, forms a fourth
branch of the HIT superfamily. Finally, the GalT enzymes, which exert speciﬁc nucleoside monophosphate
transferase activity, form a ﬁfth branch that is not implicated in tumorigenesis. The molecular mechanisms by
which the HINT and FHIT proteins participate in bioenergetics of cancer are just beginning to be unraveled. Their
purportedactions as tumor suppressors are highlighted in this review. This article is part of a Special Issue entitled:
Bioenergetics of Cancer.ergetics of Cancer.
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Proteins containing the HIT domain constitute a superfamily of
enzymes that share the motif, His-ϕ-His-ϕ-His-ϕ–ϕ, where ϕ is a
hydrophobic aminoacid.When considered according to their enzymatic
activity, HIT proteins are classiﬁed as nucleoside phosphoramidate
hydrolases, dinucleotide hydrolases or nucleotidylyl transferases. HIT
proteins bind nucleotides in such a way that the His-ϕ-His-ϕ-His-ϕ–ϕ
active site is positioned vis-à-vis the α-phosphate of the substrate. The
key difference between the HIT hydrolase and the transferase activity is
that the hydrolases do not require a second substrate to accept the
histidine bound nucleotide but are able to transfer the nucleotide to
water [1]. Mutation of the secondHis in the histidine triad abolishes the
hydrolase activity of HIT proteins [2].
The HIT proteins have been conserved throughout evolution,
which implies that they fulﬁll basic, perhaps vital functions [3]. More
than 35 members of the HIT superfamily have been identiﬁed in 29
species including bacteria, archae, yeast, plants, C. elegans, Drosophila
and mammals. The human genome encodes 7 HIT proteins, which can
be classiﬁed into 5 branches (Fig. 4) [4].2. HINT proteins (HIstidine Triad NucleoTide-binding proteins)
HINT (nomenclature: human HINT, non-human Hint) proteins
constitute the ﬁrst branch of the HIT superfamily. At least one HINT/
Hint is present in all fully sequenced genomes. The human genome
contains 3 separate genes that encode the HINT1, HINT2 and HINT3
gene products.
2.1. HINT1
HINT1 (HIstidine triad NucleoTide-binding protein 1), a 126 amino
acid (Fig. 1), cytosolic protein, was ﬁrst reported in 1990 to be a protein
kinase C inhibitor [5] and appears in early literature as Protein Kinase C
Inhibitor-1 (PKCI-1) [6–18]. The PKC inhibitory role is now viewed with
skepticism although HINT1 may interact directly or indirectly with PKC
[19] and therefore PKCI-1 was renamed HIstidine triad NucleoTide-
binding protein 1 [20]. According to structural studies by crystallography
and NMR spectroscopy HINT1 is a purine nucleotide-binding protein
[20–22]. HINT1 forms homodimers and each subunit binds a nucleotide.
Brenner and coworkers discovered that HINT1 can hydrolyze
adenosine 5′-monophosphoramidate (AMP-NH2), an intracellular solute
that is synthesized from AMP-SO4 and ammonia in many eukaryotic
organisms [2,23,24]. This monophosphoramidase activity is dependent
upon the secondHis residue of theHIT domain since aHis→Alamutation
abolishes this enzymatic activity [2]. The physiological importance of
AMP-NH2 is unknown and it is perhaps not the natural substrate of
HINT1. HINT1 can hydrolyze AMP adducts bound to lysine residues of
Fig. 1. Alignment of the amino acid sequences of human HINT1, HINT2, HINT3 and FHIT proteins. The histidine triad motif (His-φ-His-φ-His-φ–φ) is indicated (arrow) and mediates
the nucleotide binding. The middle His of the motif is essential for hydrolase activity. The HINT1/HINT2/HINT3 proteins and the FHIT protein belong to two separate branches of the
HIT superfamily. The Tyr at position 114 of FHIT (red arrow) is required for pro-apoptotic activity.
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of protein substrates [1]. Chou et al. investigated the substrate speciﬁcity
of HINT1 using a sensitive, continuous ﬂuorescence-based assay to
measure the phosphoramidate hydrolase activity. HINT1 showed a clear
preference for purine over pyrimidine phosphoramidates [25].
Using puriﬁed lysyl-tRNA synthetase, Chou and Wagner identiﬁed
lysyl-AMP as a substrate for HINT1, which yields an adenylated form of
the enzyme [26]. This ﬁnding has focused attention on the contribution
that HINT1 could make to a variety of cellular functions. Aminoacyl-
tRNA synthetases are the essential enzymes that charge amino acids
with their corresponding cognate tRNAs to form aminoacyl-tRNAs. The
reaction proceeds by the formation of an aminoacyl-AMP intermediate.
Aminoacyl-tRNA synthetases have pleiotropic physiological roles in
transcription, translation, splicing, inﬂammation, angiogenesis and
apoptosis [27]. Several aminoacyl-tRNA synthetases (E, I, L, R, Q, M, K,
D) associate with three aminoacyl-tRNA synthetase-interacting multi-
functional proteins (AIMP), AIMP1/p43, AIMP2/p38 and AIMP3/p18 to
form macromolecular complexes. AIMP1 is a precursor of endothelial
monocyte-activating polypeptide-II, is secreted as a proinﬂammatory
cytokine and increases proliferation and collagen production in
ﬁbroblasts, induces migration of endothelial cells and activates macro-
phages [28]. AIMP2 is a proapoptotic factor that interacts with p53 [29],
and AIMP3 is a tumor suppressor that activates repair of damaged DNAFig. 2. Proposed mechanism of adenylation of HINT1. HINT1 can associate with and thereb
upstream stimulatory factor 2 (USF2) in a complex with lysyl-tRNA synthetase (LysRS). Lys
the formation of Ap4A. HINT1 is dissociated from the complex by binding to Ap4A. The His res
adenylated enzyme intermediate. HINT1 hydrolyzes lysyl-AMP.[27]. Lysyl-tRNA synthetase is required to lend stability to the complex
[30]. Surprisingly, human lysyl-tRNA synthetase was found to be
secreted from various cell lines and to interact with cell surface
chemokine receptors to stimulate the formation of TNFalpha. Trypto-
phanyl and tyrosyl-tRNA synthetases are also procytokines but are not
generally associated with the complex [31,32].
Most of the experimental evidence supports a role for HINT1 in
the regulation of transcription that could affect tumorigenesis
signaling pathways. Razin and coworkers documented a functional
multiprotein interaction between Hint1, lysyl-tRNA synthetase and
the microthalmia transcription factor (MITF), a melanoma oncogene
whose expression transforms primary human melanocytes and
increases their chemo-resistance [33], as well as with the upstream
stimulatory factor 2 (USF2), an oncogene ubiquitously expressed in
eukaryotic cells [34,35]. Besides its function in the aminoacylation of
tRNA, lysyl-tRNA synthetase produces the signaling molecule,
diadenosine tetraphosphate (Ap4A) [36]. Both MITF and USF2 are
inhibited when associated with HINT1. However, Ap4A can bind to
HINT1 and provoke the dissociation of HINT1 fromMITF or USF2 and
allow trans-activation (Fig. 2). HINT1 was associated physically with
the basal transcription factor TFIIH via an interaction with the cyclin
dependent kinase Cdk7 [2,11]. A similar interactionwas reported in S.
cerevisiae, between Hnt1 and Kin28, which are the yeast orthologuesy inhibit transcription factors such as microphthalmia transcription factor (MITF) and
RS synthesizes aminoacyl-tRNA via an aminoacyl-AMP intermediate and also catalyzes
idue of the HIT domain binds to the substrate, lysyl-AMP generated by LysRS, to form an
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Kin28 resulted in elongated cells and reduced colony formation, a
phenotype not apparent after disruption of Hnt1 alone [11]. However,
studies in Hint1−/−mice failed to show a phenotype consistent with a
role for Hint1 in the regulation of Cdk7 activity [37]. Weiske and Huber
identiﬁed an interaction between HINT1 and the β-catenin partners,
pontin and reptin. In functional experiments, HINT1 acted as a negative
regulator of TCF-β-catenin transcriptional activity, thereby repressing
the expression of target genes of the Wnt signaling pathway such
as axin2 and cyclin D1 [18]. In pull-down assays, HINT1 did not bind to
β-catenin or LEF-1 nor did it impair the LEF-1/β-catenin interaction or
the binding of pontin or reptin to β-catenin. Rather, HINT1 disrupted
pontin/reptin complexes and was able to bind to the histone acetylase
Tip60 [38]. This suggests that HINT1/Tip60 complexes have a repressive
function at least on a subset of TCF/β-catenin target genes.
Transient transfection of HINT1 into SW480 and MCF-7 cells
induced apoptosis associated with increased expression of p53, Bax
and decreased expression of Bcl-2. The silencing of HINT1 down-
regulated the expression of p53 and Bax. HINT1 was retrieved from
the Bax promoter in a complex with Tip60 [39].
Su et al. reported that mice lacking Hint1 developed more tumors
when treated with a carcinogen [17]. Not only Hint1−/−mice, but also
Hint1+/−miceweremore susceptible to the induction ofmammary and
ovarian tumors than wild-type mice [40]. In an effort to elucidate
mechanisms of tumor suppression, Weinstein's group discovered that
Hint1 binds to the protein ‘plenty of SH3 domains’ (POSH), a scaffold
protein that participates in a multimeric complex with Rac-1, mixed
lineage kinase 3(MLK3), MAPK kinase 4/7 and JNK1/2 [41,42]. POSH
increases JNK activation and apoptosis and its ectopic expression
stimulates nuclear translocation of NF-κB [43]. The overexpression of
POSH promotes neuronal apoptosis and the silencing of POSH with
antisense oligonucleotides and siRNA suppresses JNK activity and
neuronal apoptosis induced by NGF withdrawal [44] and prevents
ischemic injury by inhibiting the MLK3-MAPK kinase 4-JNK signalling
pathway and caspase 3 activation [45]. Apoptotic stimuli increase
endogenous cellular levels of POSH and MLKs, an effect that occurs
through protein stabilization [46]. The Hint1/POSH interaction impairs
the ability of JNK2 to phosphorylate activator protein 1 (AP-1), which is
an important transcription factor in cancer cells [41]. In addition to
inhibiting AP-1 transcription activity, HINT1 also interacts with and
suppresses the S-phase-kinase-associated protein 2 (SKP2) SCF ubiqui-
tin ligase complex, which regulates the ubiquitination of the cell
cycle regulator, p27KIP1 [47]. The particular importance of HINT1 in
hepatocellular carcinoma has garnered special attention along with
other tumor suppressors implicated in liver carcinogenesis. The
promoter of HINT1 is frequently hypermethylated in hepatocellular
carcinoma, and this is associated with a lower expression of HINT1 in
tumor tissue [48]. HINT1 can thus be added to the list of tumor
suppressor genes subject to DNA promoter methylation as a means of
transcriptional inactivation [49]. The extent of HINT1 hypermethylation
was even correlated with the prognosis of HCC [50]. The poorer the
prognosis of HCC, the greater the extent of gene hypermethylation and
the lower the expression level ofHINT1protein. Theﬁndings of Calvisi et
al. imply that HINT1 inﬂuences the activity of SKP2, which in turn yields
more degradation of the cell cycle regulator, p27KIP1, all features of HCC
with a poor prognosis. An additional discovery that likely inﬂuences the
tumor suppressor properties of HINT1, is its participation in repair of
DNA double strand breaks [51]. Mouse Hint1 co-immunoprecipitated
with γ-Histone 2AX and ATM (ataxia-telangiectasia mutated) protein
kinase after ionizing radiation-induced DNA damage, an event that
normally activates and recruits bothproteins to the focus of DNAbreaks.
Hint1−/−mouse embryonic ﬁbroblasts are more resistant to cytotoxicity
and apoptosis after ionizing radiation [17], presumably becauseHint1 can
no longer regulate the functions of γ-Histone 2AX and ATM [51].
Evidence of biological functions of HINT1 in neurons was recently
uncovered. The C terminus of the μ-opioid receptor binds to HINT1,which in turn binds to another protein, RGS-z, amember of the family of
regulator of G-protein signaling (RGS) proteins. Cerebroventricular
administration of morphine recruits PKC isoforms to the μ-opioid
receptor via a HINT1/RGS-z complex. When HINT1 expression was
lowered, morphine produced stronger analgesic effects and neither the
PKCγ- μ-opioid receptor complex nor serine phosphorylation of this
receptor was detected [52]. Microarray studies reported decreased
mRNA expression of HINT1 in the frontal cortex of individuals with
schizophrenia, suggesting a link to the pathophysiology of the disease
[53,54]. Consistent with the documented link between dopamine
transmission and schizophrenia, systemic administration of the direct-
acting dopamine receptor agonist apomorphine signiﬁcantly increased
locomotor activity in Hint1−/− mice in contrast to control mice [55].
Moreover, apomorphine elicited anxiolytic and anti-depressant like
properties in Hint1−/−mice [55].
Despite the ongoing productive research in the ﬁeld, the authentic
function of HINT1 in cellular physiology remains elusive. The speciﬁc
residues engaged in the binding of nucleotides are those conserved
residues in the domain shared by the HIT families [22], which supports
the notion that nucleotide binding is an inextricable part of HINT1's
function. Unlike its binding to nucleotides, the binding of HINT1 to other
protein partners hasnot gathered the samedegreeof structural scrutiny.
Identifying the structural motifs that mediate HINT1–protein interac-
tions and determining whether nucleotidyl hydrolase activity ever
factors into its tumor suppressor properties are outstanding scientiﬁc
questions. As more experiments with theHint1 gene knockoutmice are
conducted, the contribution of HINT1 to normal physiology and to
tumorigenesis will be elucidated.
2.2. HINT2
We identiﬁed human HINT2, a protein with 61% identity to HINT1,
by screening a liver library (Fig. 1). Using real-time quantitative PCR
and immunoblotting with a speciﬁc antibody, we discovered that
HINT2 is predominantly expressed in the liver and the pancreas. Using
immunohistochemistry, transfection with HINT2 ﬂuorescent chimeric
proteins and isolation of mitochondria, we determined that HINT2 is
located in the mitochondria matrix [56].
Since HINT1 was ﬁrst described to be a PKC inhibitor [5,57,58], we
investigated whether HINT2 inhibited PKC. In a PKC activity assay,
afﬁnity-puriﬁed HINT2 did not inhibit the phosphorylation by PKC
either of histone or of myelin basic protein, which discounts HINT2 as
a PKC inhibitor. We tested whether HINT2 was a PKC substrate, since
its sequence contains a potential PKC phosphorylation site (122TAK),
albeit within an α-helix. In contrast to histone, HINT2 was not
phosphorylated by a rat brain fraction enriched in PKCs. Neither
overlay, nor co-immunoprecipitation revealed an interaction between
HINT2 and protein kinase C isoforms [56].
Consistent with the fact that HIT proteins contain a nucleotide
binding domain, Bieganowski et al. reported that substrates hydrolyzed
at rates greater than 1 mmol·min−1·μg−1 by Hint1 are adenosine
5′-monophosphoramide-linked compounds [2]. Hint1 also hydrolyzed
AMP linked to a lysine side chain [59]. Given the high homology of
HINT2 with HINT1, HINT2 was tested for an adenosine phosphorami-
dase activity. Using the model compound AMP-pNA, in which a
paranitroaniline reporter is linked by a phosphoramidase linkage to
AMP [2], we found that puriﬁed HINT2 had phosphoramidase activity,
characterized by a kcat of 0.0223±0.0031 s−1 and a Km of 128±35 μM.
In contrast, rabbitHint1 activitywas characterized by a kcat of 0.00187±
0.00006 s−1 and a Km of 134±11 μM. Therefore, the kcat/Km of HINT2 is
10-fold larger than that of Hint1. When the middle histidine of the
HIT motif of HINT2 was mutated to an alanine (HINT2–H149A), the
adenosine phosphoramidase activity was lost.
Theﬁnding thatHINT2displays adenosinephosphoramidaseactivity
and unlike HINT1, is located in the mitochondria, an organelle required
for ATP synthesis and adenosine metabolism, broadens the search for
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cascade of apoptosis signals, which are triggered either extrinsically by
the activation of death receptors or intrinsically by the disruption of
intracellular homeostasis. Permeabilization of the mitochondrial mem-
branes dissipates the potential of the inner membrane and allows the
leakage of caspase-activating proteins into the cytoplasm,which in turn
mediate apoptosis. InHepG2 cells overexpressingHINT2, the incubation
with an antibody against Fas and actinomycin D induced greater
changes in the mitochondrial membrane potential than in control
HepG2 cell and the abundanceof cleaved PARPand cleaved caspases 3, 7
and 9 was higher in the cells overexpressing HINT2. In the cell lines
transfected with the hydrolase-negative HINT2–H149A and expressing
less HINT2, exposure to anti-Fas antibody and actinomycin D resulted in
less change in the mitochondrial membrane potential and less cleaved
caspase 3.
In order to determine whether HINT2, like HINT1 displays tumor
suppression properties, we assessed in vivo the inﬂuence of Hint2 on
tumor growth. HepG2 cells were injected into the ﬂank of SCID mice.
HINT2-overexpressing HepG2 cells formed signiﬁcantly smaller
tumors than control HepG2 cells. This was associated with more
cleaved caspase 9, uncleaved PARP and more apoptosis. This
prompted us to analyze the expression of the HINT2 gene in several
types of human tumors. Microarray analysis revealed that HINT2
expression was signiﬁcantly reduced in hepatocellular carcinoma, but
not in the surrounding cirrhotic tissue. In contrast, the expression of
HINT1 and HINT3 mRNAs was not reduced in human hepatocellular
carcinoma. HINT2 mRNA was less abundant in the subclass of HCC
with a poor prognosis than in the subclass with better prognosis. Real-
time quantitative PCR showed lower expression of HINT2 mRNA in
breast carcinomas and in colon carcinomas than in normal tissue.
Since themost important regulatory steps of steroidogenesis occur
in the mitochondria, we studied the role of HINT2 in the biosynthesis
of pregnenolone in H295R adrenocortical cells [60]. When over-
expressed, HINT2 effected no change in pregnenolone secretion elicited
byangiotensin II orK+,whereaswhenHINT2was silencedwith a speciﬁc
siRNA, the steroidogenic response was reduced. Similarly, when HINT2
was overexpressed, the mitochondrion calcium signal did not change,
whereas after silencing of HINT2, the duration of the mitochondrial
calcium signal induced by angiotensin II was reduced. After HINT2
silencing, pregnenolone secretion was also reduced in response to
activation of the cAMPpathwayby forskolin and after exposure to 25-OH
cholesterol, which bypasses the rate-limiting and Ca2+-dependent step
ofmitochondrial import. Theseﬁndings suggestthatHINT2 is required for
an optimal steroidogenic response to both Ca2+-dependent and Ca2+-
independent agonists but its role is not rate-limiting [60].
2.3. HINT3
A third human HINT gene is located at 6q22.33. HINT3 is predicted to
encode a 182 amino acid proteinwith a 31 and25 amino acid extension at
the N and C terminus, respectively (Fig. 1) and is expressed in both
cytosolic andnuclear compartments. HINT3 can assemble intomultimeric
oligomers and its substrate preference is acyl-adenylates over nucleoside
phosphoramidates [61]. At present, no studies have investigated the
expression or role of HINT3 in tumor formation or progression. We have
generated Hint3−/−mice and are currently characterizing them.
2.4. Hint proteins in bacteria
The smallest of bacterial genomes (Mollicutes) [62] encode a Hint
protein, therefore Hintsmay have been present at the cellular origin of
life. In E. coli, the Hint orthologue echinT shares 50% identity with
HINT1 and is essential for growth under high salt conditions [63].
EchinT forms stable interactions with a putative oxidoreductase, a
formate dehydrogenate (bl501), the heat shock protein 70, the beta-
subunit of DNA polymerase III, a membrane bound lytic mureintransglycosylase D, ET-Tu elongation factor (tufA) and a putative
synthetase (yjhH) [64].
3. Aprataxin
In 2001, linkage analysis showed that the APTX gene located on
chromosome 9, was mutated in patients with ataxia–ocular apraxia, a
neurological disorder with symptoms that resemble those of ataxia-
telangiectasia, which is a syndrome characterized by an abnormal
response to double-strand DNA breaks and genome instability [65,66].
APTX encodes Aprataxin, which is expressed in two splice forms and is
located in the nucleus and nucleolus. In addition to a HITmotif, Aprataxin
contains a C-terminal putative zinc ﬁnger domain, which can bind DNA
[4,67] A third domain, the forkhead-associated domain, is present in the
major splice form of Aprataxin, and this domain mediates the interaction
with ligase cofactors, the x-ray cross-complementing proteins (XRCC).
Althoughpreviously classiﬁedas amemberof theHINTbranchhydrolases
[1], amore recent phylogenetic analysis indicates that Aprataxinwarrants
its place in a separate branch of the HIT superfamily [4].
Aprataxin possesses AMP-lysine and GMP-lysine hydrolase activity
[68], and this encouraged the notion that reversal of nucleotidylylated
protein modiﬁcations somehow underlies the biological actions of
Aprataxin. Yeast two-hybrid system and co-immunoprecipitation studies
found that Aprataxin interacts with the DNA repair proteins XRCC1 and
poly(ADP-ribose) polymerase-1 (PARP-1) as well as with p53 [69]. Cells
carrying a mutation in Aprataxin are more sensitive to the DNA
topomerase I inhibitor, camptothecin, which induces DNA single-strand
breaks [70] anda role forAprataxin inDNA single-strand-break repair and
in multiple DNA repair pathways has been documented recently [67,71].
At themolecular level, Aprataxin removes 5′AMPatDNA standbreak sites
[72]. Neurological disorders associated with Aprataxin mutations have
beenattributed to theaccumulationofunrepairedDNAstrandbreaks [72].
In yeast genetic studies, deletion of the S. cerevisiae of the Hnt3 gene,
homolog of Aprataxin, renders cells hypersensitive to DNA damaging
agents when combined with a deletion in the ﬂap endonuclease, Rad27,
which results in deﬁciency in long-patch base excision repair [73]. The
authors concluded that Hnt3/Aprataxin and ﬂap endonucleases could
process adenylated 5′ends of DNA in parallel. An association between
coenzyme Q10 deﬁciency and a mutation in Aprataxin was identiﬁed in
members of one family diagnosed with ataxia [74]. Microarray analysis
of colorectal cancer cell lines showed a signiﬁcant negative correlation
between mRNA expression levels of Aprataxin and sensitivity to
camptothecin-induced apoptosis [75]. Furthermore, a tissuemicroarray
of tumor samples fromcolorectal cancer patientswhowere treatedwith
the camptothecin analog, irinotecan, could distinguish a group with
good response to therapy and who had longer progression free and
overall survival when their tumor expressed less Aprataxin. The
potential for Aprataxin expression levels to serve as a biomarker for
the classiﬁcation of tumors amenable to treatment awaits conﬁrmation.
4. FHIT (Fragile HIT protein)
The FHIT gene is located within a fragile region of chromosome 3 of
the human genome and is frequently altered in cancers and inactivated
in cancer-derived cell lines [76]. The FHIT protein possesses a HIT motif
and is a tumor suppressor. FHIT is absent or reduced in many types of
human tumors including lung, esophagus, stomach, kidney and cervical
carcinomas [77,78]. Deletions are observed in preneoplastic lesions of
lung, cervix and breast [79]. Fhit−/− mice survive but spontaneously
develop tumors more frequently than control mice [80]. Mice carrying
one inactivated Fhit allele (Fhit+/−) are highly susceptible to chemical
induction of tumors [81].
Although ﬁrst identiﬁed as a cytosolic protein, FHIT can be directed
to the mitochondria upon interaction with the chaperones Hsp60 and
Hsp10, where it interacts with ferredoxin reductase, a ﬂavoprotein
transactivated by p53 and responsible for transferring electrons from
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recognized as essential to its tumor suppressor actions via apoptosis.
The FHIT/ferrodoxin reductase complex generates reactive oxygen
species and increases calcium uptake into the mitochondria to
potentiate the effects of apoptotic agents [83].
The FHIT enzyme hydrolyzes dinucleoside polyphosphates (ApnA)
although this hydrolysis appears to be independent from its
tumor suppressor properties. Intracellular diadenosine 5′,5‴-P1,Pn
polyphosphates (ApnA, n=3–6) are signaling molecules whose
concentrations are labile. Intracellular Ap4A is increased in proliferating
mammalian cells [84] and during liver regeneration [85,86]. Ap3A is
synthesized by tryptophanyl-tRNA-synthetase which, in contrast to
other amino acyl tRNA synthetases, cannot produce Ap4A. FHIT
hydrolyzes Ap3A to produce ADP and AMP [87], an enzymatic activity
that was puriﬁed from rat liver in 1977 [88] but remained an orphan
reaction until the discovery of FHIT. A mutated FHIT having lost Ap3A
hydrolase activity remains a nucleotide binding protein and a tumor
suppressor [89]. An active signaling role was ascribed to the nucleotide-
bound FHIT complex as a means of explaining the independence of the
tumor suppressor and hydrolysis activities [89].
The tumor suppressor properties of FHIT are related to its pro-
apoptotic effects. Human lung cancer cell lines overexpressing FHIT
are less tumorigenic in nude mice and more frequently apoptotic
[90,91]. Experimental evidence exists for protein interactions between
FHIT and the MDM2 phosphoprotein, which interacts with p53 [92].
The FHIT-mediated inactivation of MDM2 blocked the association of
MDM2 with p53, leading to the stabilization of p53 in human non-
small cell lung carcinoma cells. Thus tumor cell growth was inhibited
by coexpression of FHIT and p53 [92]. When FHIT expression was
restored in FHIT-negative cell lines, caspase 8 was activated and
apoptosis was induced [93]. These reports all indicate that FHIT can
inhibit tumor growth in part via an apoptotic pathway. More recently,
FHIT was found to be phosphorylated at Tyr 114 by Src kinase and to
negatively regulate the central signaling molecule Akt [94] (Fig. 3).Fig. 3. The proposed mechanisms underlying the induction of apoptosis by the fragile HIT
increases. ApnA are substrates for FHIT and formation of ApnA·FHIT is required for apopt
activation of caspase 8. FHIT can also bind to the Hsp60/10 chaperone complex, which direct
Reactive oxygen species (ROS) are produced, which engages the mitochondrial apoptotic pat
Tyr 114, which targets FHIT for proteosomal degradation.Other molecular mechanisms must be considered to explain FHIT
antitumoral activity. Weiske et al. overexpressed FHIT and β-catenin in
HEK293 cells and showed that FHIT repressed transcriptional activity of
β-catenin by direct interactionwith its C-terminus and thereby regulated
transcription of target genes such as cyclin D1 [95]. Therefore loss of FHIT
would promote a deregulation of this pathway with consequences on
proliferation, differentiation, and apoptosis.Woenckhaus et al. conﬁrmed
this hypothesis by immunohistochemical analysis of non-small cell lung
cancer. They observed a loss of FHIT expression associated with poor
prognosis and β-catenin expression [96]. Nakagawa and Akao over-
expressed FHIT in the human colon cancer line, SW480, and reported a
reduction in the phosphorylation of IκB-α [97]. The silencing of FHITwith
siRNA promoted the phosphorylation and degradation of IκB-α resulting
in the activation and nuclear translocation of NF-κB. In this experimental
situation therefore, the anti-tumoral action of FHIT was attributed to the
blocking NF-κB signaling pathway [97]. The role of FHITmay be different
in metastatic tumors. The expression levels of various tumor associated
proteins were determined by immunohistochemistry in tissue arrays
of primary and metastatic gastric carcinoma. The level of FHIT as well as
β-catenin and NF-κB was lower in gastric carcinoma metastasis than in
primary tumors [98]. However, FHIT immunonegativity in the primary
tumor was inversely correlated with advanced lymph node metastasis
[98]. Other candidate FHIT-interacting proteins have been reported. FHIT
co-immunoprecipitated with the ubiquitin-conjugating enzyme hUBC9
[99], suggesting ameans of regulating the degradation of cell cyclins. The
interaction with hUBC9 was subsequently shown to be dependent on
Ap3A binding to FHIT, although the hUBC9-FHIT binding complex was
devoid of hydrolase activity [100]. The importance of the hUBC9-FHIT
interaction awaits conﬁrmation in an experimental tumor model.
5. Scavenger mRNA decapping enzyme, DcpS
The 3′→5′ mRNA exonuclease degradation pathway generates
small, 5′-capped (m7GpppN) mRNAs, which then become substratesprotein, FHIT. In response to cellular stress, the level of diadenosine polyphosphates
osis. FHIT can mediate apoptosis through the cytoplasmic pathway triggered by the
s the bound protein to the mitochondria where it stabilizes ferrodoxin reductase (Fdxr).
hway. FHIT also inactivates PI3K-Akt-Survivin signals. Src kinase phosphorylates FHIT at
Fig. 4. Family of human hit proteins.
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(DcpS), a HIT protein expressed in the cytoplasm and nucleus
[101,102]. The hydrolysis of m7GpppG by DcpS yields m7GMP and
GDP. An extensive structure–activity relationship study indicated that
the methylated base is an essential feature of the ligand and that cap
analogues containing pyrimidine bases are not used as substrates
[103]. The expression of DcpS is induced by the stress signals that
result in the production of aborted mRNA transcripts. Delta-
lactoferrin, a transcription factor involved in the regulation of cell
cycle progression at the G1/S transition, activates DcpS transcription
[104]. Information regarding the phenotype of animals in which the
DcpS gene is disrupted is not yet available but by analogy with
disruption of the yeast ortholog (dcs1Δ), DcpS regulates 5′ to 3′
exonucleolytic activity, which causes accumulation of short capped
oligonucleotides as well as uncapped stable mRNAs [105]. As
proposed by Bail and Kiledjian, it is logical that a reduction in the
function of DcpSwould cause an overall malfunction inmRNA splicing
and decay, thereby modulating gene expression with consequences
for tumorigenesis [106]. The most recent information concerning
DcpS in human disease has identiﬁed DcpS as amolecular target of C5-
quinazolines. Inhibition of DcpS by C5-quinazolines was associated
with an increase in expression of the SMN2 gene, which can
complement the defective levels of the survival motor neuron
(SMN) protein that causes spinal muscular atrophy [107].6. Galactose-1-phosphate uridylyltransferase (GalT)
The liver enzyme galactose-1-phosphate uridylyltransferase
(GalT) catalyzes the transfer of UMP from UDP-glucose to galactose-
1-phosphate to produce UDP-galactose and glucose-1-phosphate.
GalT represents a separate branch of the HIT protein superfamily, which
operates as a transferase rather than as a hydrolase. Its nucleotide
transfer proceeds via a covalent intermediate formed between UMP and
a His residue from its modiﬁed HIT motif, His-ϕ-His-ϕ-Gln-ϕ–ϕ.
Mutations in the GalT gene result in galactosemia, a disease
characterized by a failure to thrive, cataracts and mental retardation
[1]. Unlike the other HIT proteins, GalT has a deﬁned role in
carbohydrate metabolism and is not implicated in tumorigenesis.In conclusion, the HIT superfamily represents a diverse group of
proteins, united by their structural motif but divergent in their tissue
distribution, subcellular location, enzymatic activities and importance
in tumorigenesis. As it now stands, the HINT and FHIT proteins have
conﬁrmed tumor suppressor activities, which could be mediated
through regulation of transcription factors and pro-apoptotic mech-
anisms, and appears be independent of enzymatic activity. Within the
HINT branch, we are most knowledgeable about the HINT1 protein, in
terms of its expression in tumors and its purported mechanisms. Our
study of, and appreciation for the signiﬁcance of the HINT2 and HINT3
proteins lag far behind.
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